Sorafenib-induced palmoplantar hyperkeratosis

Area of Science:

• Oncology
• Dermatology
• Pharmacology

Background:

• Sorafenib is an oral multikinase inhibitor utilized for treating advanced renal cell carcinoma.
• Cutaneous adverse events are recognized side effects of kinase inhibitors, including sorafenib.
• Hand-foot reaction, characterized by hyperkeratosis, is a known complication.

Observation:

• A 51-year-old female patient with metastatic renal cell carcinoma developed tender, erythematous callosities on her fingers and feet.
• These symptoms emerged after an increase in her sorafenib dosage.
• While a dose reduction alleviated some symptoms, the hyperkeratosis remained.

Findings:

• The patient's presentation suggests a distinct cutaneous reaction to sorafenib.
• The persistent hyperkeratosis, despite dose modification, differentiates this event from typical hand-foot syndrome.
• This highlights a potential novel adverse drug reaction associated with sorafenib therapy.

Implications:

• Further investigation into the specific mechanisms of sorafenib-induced hyperkeratosis is warranted.
• Clinicians should be aware of this distinct presentation when managing patients on sorafenib.
• This finding may inform future treatment strategies and patient monitoring for sorafenib-related skin toxicities.